WO2006064906A1 - 非晶質性組成物 - Google Patents
非晶質性組成物 Download PDFInfo
- Publication number
- WO2006064906A1 WO2006064906A1 PCT/JP2005/023140 JP2005023140W WO2006064906A1 WO 2006064906 A1 WO2006064906 A1 WO 2006064906A1 JP 2005023140 W JP2005023140 W JP 2005023140W WO 2006064906 A1 WO2006064906 A1 WO 2006064906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- composition according
- amorphous
- preparation
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to an amorphous composition.
- the present invention relates to amorphous (2R) -N- (1-benzylpiperidine mono-4-yl) 3 cyclohexylmethylthio-2- [(4R) 3-t-butoxycarbonyl
- the present invention relates to a pharmaceutical composition comprising thiazolidine 4-ylcarbolamino] propanamide or a salt thereof and an amorphous polymer.
- Compound (I) or a salt thereof is effective as a preventive and Z or therapeutic agent for diseases based on retinal ischemia (such as glaucoma, diabetic retinopathy, macular degeneration, or retinal vascular occlusion) ( (See Patent Document 2).
- retinal ischemia such as glaucoma, diabetic retinopathy, macular degeneration, or retinal vascular occlusion
- BA bioavailability
- compound (I) is metabolized by the metabolic enzyme CYP 3A4
- oral administration has a first-pass effect in the small intestine and liver, which is thought to be the cause of low BA.
- the amount of metabolic enzyme varies greatly among individuals, when administered orally, the variation in plasma concentration varies greatly, making it difficult to use as an oral preparation.
- the crystalline compound can withstand long-term storage that is resistant to changes over time, the solubility in a solvent such as water in the crystalline state is higher than that in the amorphous state. Generally not high.
- the amorphous form generally has a high solubility unlike the crystal form and is easily taken into the living body. Therefore, in order to increase the absorption of the drug, the amorphous form is maintained for a long period of time.
- a stable formulation that can be desirable is desirable.
- Patent Document 1 International Publication No. 00Z00470 Pamphlet
- Patent Document 2 Pamphlet of International Publication No.02Z51431
- Patent Document 3 Specification of Patent 2984661
- Patent Document 4 International Publication No.04Z113332 Pamphlet
- An object of the present invention is to provide a novel pharmaceutical composition in which the above-mentioned problems of compound (I) or a salt thereof are improved.
- an object of the present invention is to provide compound (I) or a salt thereof as an amorphous composition with improved chemical and physical stability, and as a result, compound (I) The BA can be improved.
- composition according to the above item [1] which is an amorphous polymerized hydroxypropylmethylcellulose acetate succinate or hydroxypropylcellulose;
- composition according to the above item [1] which is an amorphous polymerized hydroxypropyl methylcellulose acetate succinate,
- composition according to [3] which is a preparation for nasal administration
- composition according to [7] wherein the powder has an average particle size of 100 ⁇ to 150 / ⁇ m
- composition according to [8] above which is an oral mucoadhesive tablet or oral mucosa-adherent film preparation
- composition according to [3] above which is a spray-dried granulated product or a stirred granulated product
- composition according to [3] above which is a therapeutic and / or preventive agent for pain
- Compound (I) or a salt thereof can be produced according to a known method, for example, the method described in WO 00Z00470.
- stability refers to the degree to which a state is physically and theoretically maintained.
- the stability depends on the influence of the external environment such as temperature and humidity, the temperature dependence of the chemical reaction of the drug product itself, that is, the magnitude of the activation energy of the reaction, and the temperature dependence of the material's container permeability. to differ greatly.
- physical stability refers to the degree to which the compound (I), which is an active ingredient of a pharmaceutical, is not crystallized and maintains an amorphous state.
- chemical stability means that a compound serving as an active ingredient of a pharmaceutical is oxidized and transferred.
- the degree to which the compound remains without being subjected to changes in the chemical structure such as dehydration that is, the degree to which the compound remains after being stored under a certain period of time (residual rate)
- a compound in a stable state for example, a crystalline form
- a solubility in water and other solvents in the crystalline state is generally not high compared to the amorphous state.
- the amorphous form generally dissolves and is immediately taken into the living body unlike the crystal form! Therefore, in order to maintain high drug absorption, this amorphous form is maintained. To be able to A preparation that can be prepared is desirable.
- the nasal preparation can avoid the first-pass effect, it contributes to the improvement of BA as compared with oral administration, and at the same time, it can suppress variation in absorption among individuals due to a difference in genes such as metabolic enzymes.
- the pain to be treated by Compound (I) or a salt thereof for example, neuropathic pain, cancer pain, intractable pain, postoperative pain, acute pain , Chronic pain, neuralgia, infectious pain, etc.
- it does not require water when taking, it is easy to handle, so it is also suitable for use.
- oral mucosa absorbents for example, oral mucosa-adhering tablets, oral mucosa-adhering film agents, etc.
- the oral mucosa-absorbing preparation is a dosage form in which the preparation is applied to the oral mucosa such as gums, heels, and soft palate for the purpose of local or systemic action, and high BA is achieved by avoiding the first-pass effect. I can expect. In addition, no water is required for taking, and patient compliance can be kept high. There is also an advantage that no special device is required. Therefore, the oral mucosa absorbent of compound (I) or a salt thereof can be a useful preparation.
- the “amorphized polymer” includes all compounds (I) or salts capable of being converted into an amorphous form.
- amorphized polymer for example, HPMCAS and HPC (hydroxypropylcellulose) are preferred, and HPMCAS is particularly preferred. Yes.
- HPMCAS refers to (1) two types of ether substituents (methyl and / or 2-hydroxypropyl) and (2) two types of ester substituents ( Acetyl and Z or succinyl), and chemically represented as O- (2-hydroxypropyl) -O-methyl-cellulose acetate succinate.
- HPMCAS A commercially available product can be used as HPMCAS.
- HPMCAS include Shin-Etsu AQOAT—LF, Shin-Etsu AQOAT—MF, Shin-Etsu AQOAT—HF, Shin-Etsu AQOAT—LG, Shin-Etsu AQOAT—MG, Shin-Etsu AQOAT—HG Manufactured).
- HPMCAS is available from many manufacturers, but it can also be produced, for example, by treating O (hydroxypropyl) O methylcellulose with acetic anhydride and succinic anhydride (Carbohydrate 222, (1991 ), 25 5-259 and U.S. Pat. No. 4385078).
- HPC hydroxypropyl cellulose, which is made from cellulose (pulp) that exists widely in nature, treated with sodium hydroxide, and then ether such as propylene oxide. It is a nonionic cellulose ether obtained by reacting with an agent.
- HPC include HPC-SSL, HPC-SL, HPC-L, HPC-M, and HPC-H. These can be obtained as commercial products.
- Compound (I) is hardly soluble in water, but its water solubility increases under acidic conditions.
- a composition ie, a solid solution
- HPMCAS which is an acidic polymer
- the solubility in water is approximately 1.25 / z gZmL for the crystals of Compound (I)
- the amorphous composition obtained by granulating this compound with HPMCAS is about 30.3 ⁇ gZmL, An increase of more than 20 times in apparent solubility can be obtained.
- HPMCAS Hydrophilicity
- compound (I) or a salt thereof can maintain an amorphous state for a long period of time (see Test Examples 1 and 3).
- compound (I) can be stabilized as an amorphous substance, and an amorphous preparation containing compound (I) using HPMCAS as an active ingredient is stable. .
- [0047] represents a mixture of any ratio of the compounds bonded to the 13-position and the ⁇ -position
- Examples of the salt of compound (I) include pharmaceutically acceptable salts, which can be produced by known methods.
- pharmaceutically acceptable salts include alkali metal salts, alkaline earth metal salts, ammonium salts, amine salts, acid addition salts and the like.
- the salt is preferably water-soluble with little toxicity.
- Suitable salts include salts of alkali metals (strium, sodium, etc.), alkaline earth metals (calcium, magnesium, etc.), ammonium salts, pharmaceutically acceptable organic amines (tetramethylammonium).
- -Um Trietil Salt of amine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl) aminomethane, lysine, arginine, N-methyl D glucamine, etc. Can be mentioned.
- the acid addition salt is less toxic and preferably water-soluble.
- Suitable acid addition salts include, for example, hydrochlorides, hydrobromides, hydroiodides, sulfates, phosphates, inorganic salts such as nitrates, acetates, lactates, tartrates.
- Organic acids such as benzoate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, dulconate .
- Compound (I) or a salt thereof can also be converted to a solvate by a known method.
- Solvates are less toxic and are preferably water-soluble. Suitable solvates include, for example, solvates such as water and alcohol solvents (for example, ethanol).
- the amorphous composition of the present invention can be obtained using Compound (I) or a salt thereof and an amorphous polymer such as HPMCAS or HPC, but is further pharmaceutically acceptable.
- Additives can be mixed as appropriate.
- the pharmaceutically acceptable base and Z or additives include various organic or inorganic substances conventionally used as a pharmaceutical material. Examples include excipients, lubricants, binders, disintegrants, thickeners, suspending agents, emulsifiers, isotonic agents, buffers, soothing agents, stabilizers and the like. If necessary, additives such as preservatives (preservatives), pH adjusters, cooling agents, antioxidants, wetting agents and the like can be used.
- additives that can be prepared as necessary in the preparation of the present invention include the following.
- excipient examples include lactose, sucrose, D-manntol, starch, corn starch, crystalline cellulose, light anhydrous key acid, and the like.
- Examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, Examples include droxypropylcellulose, hydroxypropylmethylcellulose, polybutylpyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, and the like.
- disintegrant examples include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, L-hydroxypropylcellulose, and the like.
- Examples of the thickener include polyhydric alcohols such as glycerin and macrogol, senore mouths such as methylcellulose, canoleboxymethinoresenorelose, hydroxypropinoremethinoresenorelose, polyvinyl alcohol, Polyvinyl pyrrolidone, carboxyvinyl polymer, strength Noreboxy methinoresenorelose sodium, methinoresenorelose, hydroxymethinoresenorelose, hydroxyethyl cellulose, hydroxypropyl cellulose and other hydrophilic polymers, sodium alginate, chondroitin Examples include sulfuric acid, cyclodextrin, d-a-tocopheryl polyethylene glycol 1000 succinic acid, polyethylene glycol, and the like.
- polyhydric alcohols such as glycerin and macrogol
- senore mouths such as methylcellulose
- canoleboxymethinoresenorelose hydroxypropinoremethinoresenorelose
- suspending agent examples include stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate, polyoxyethylene hydrogenated castor oil , Surfactants such as polysorbate, polyhydric alcohols such as glycerin and macrogol, saccharides such as sorbitol, mannitol and sucrose, celluloses such as methylcellulose, carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone , Canoleboxyvininole polymer, sodium carboxymethylcellulose, methylcellulose, hydroxymethinoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresenore mouth Hydrophilic polymer such as glucose, chondroitin sulfate and the like.
- Surfactants such as polysorbate, polyhydric alcohols such as g
- Examples of the soothing agent include benzyl alcohol, chlorobutanol, propylene glycol, ethyl aminobenzoate, lidocaine and the like.
- Examples of the stabilizer include sodium sulfite, sodium hydrogen sulfite, sodium metasulfite, sodium thiosulfate, Rongalite, thioglycerol, thioglycolic acid, thiolactic acid, cysteine, dartathione, thioacetic acid, methionine, thione.
- Sulfur compounds such as sorbitol, thioglucose, thiourea, boric acid, borax, phosphoric acid, metaphosphoric acid, sodium carbonate
- Inorganic acids such as lithium and sodium bicarbonate and their salts, organic acids such as formic acid, oxalic acid, tartaric acid, citrate and edetic acid and their salts (sodium edetate), acetoamide, decylacetoamide, Acid amides such as nicotinamide, urea and valpital, urea derivatives, polyhydric alcohols such as glycol, propylene glycol, glycerin, polyethylene glycol, glucose and ascorbic acid, saccharides, phenol, thymol, quinone, coumarone, isocoumarone, etc.
- Examples include amino acids such as phenols, dibutylhydroxytoluene, glycine, glutamic acid, lysine, ferrolanine, casein
- emulsifiers examples include glycerin esters (glyceryl monooleate), saponins (such as genjusaponin, quilla extract, soybean saponin), sucrose fatty acid esters, lecithin (plant lecithin, egg yolk lecithin, soybean lecithin, etc.).
- Polyhydric alcohols oleyl alcohol, stearyl alcohol, cetyl alcohol, etc.
- fatty esters eg octyldodecyl myristate
- medium chain fatty acid triglycerides MCT
- various surfactants alkylbenzene sulfonate type emulsifiers, benzalkco chloride) -Um, sorbitan sesquioleate, dodecylbenzenesulfonic acid, etc.
- triethanolamine triethanolamine
- preservative examples include para-benzoic acid esters such as propyl noraoxybenzoate and butyl noraoxybenzoate, parabens such as methylparaben, ethylparaben, propylbaraben and butylparaben, benzalkoxy chloride , Benzethonium chloride, chlorohexidine dalconate, reverse sarcophagus such as cetylpyridium chloride, alcohol derivatives such as chlorobutanol, benzyl alcohol, phenethyl alcohol, sodium dehydroacetate, sorbic acid, sodium sorbate, etc. Organic acids and salts thereof, and phenols such as parachloromethoxyphenol and parachloromethalesol.
- para-benzoic acid esters such as propyl noraoxybenzoate and butyl noraoxybenzoate
- parabens such as methylparaben, ethylparaben, propylbaraben and
- Examples of the pH adjuster include sodium hydroxide, potassium hydroxide, trisodium phosphate, disodium hydrogen phosphate, hydrochloric acid, nitric acid, citrate, boric acid, acetic acid, phosphate buffer and the like. Can be mentioned.
- Examples of the refreshing agent include 1 menthol, dl-menthol, camphor, and hot water.
- Examples of the antioxidant include sulfite, ascorbic acid, citrate, sodium edetate, and the like.
- wetting agent examples include propylene glycol, polysorbate, macrogol, and glycerin.
- Examples of the pressure-sensitive adhesive include hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, and polyethylene oxide.
- the amorphous composition of the present invention is preferably a solid agent or powder.
- the additive used in the amorphous composition of the present invention is preferably a binder, which is crystalline cellulose, sucrose, D-manntol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polybulu. Pyrrolidone, starch, sucrose, gelatin, methylcellulose and sodium carboxymethylcellulose are all preferred, and more preferred is hydroxypropylmethylcellulose.
- the amorphous composition is obtained by, for example, converting the compound (I) or a salt thereof and a mixture of the amorphous polymer to an amorphous polymer by a method such as spray drying. It can be obtained by hesitation.
- the spray-drying method is also called spray-drying method, and it is obvious to those skilled in the art that the liquid mixture is made into small droplets (atomization) and the solvent is removed from the mixture in a container (spray-drying device). Represents a process that involves rapid removal.
- the method for converting the compound (I) into an amorphous form is not limited to the spray drying method, but the evaporator solvent distillation method, the heating and melting method, the etastruder method, the supercritical method, Methods such as mixed grinding and adsorption are also included.
- the amorphous composition obtained by the intensive method is, for example, uniformly dispersed or adhered to a solid physiologically acceptable additive, or formulated by granulation.
- an amorphous composition comprising Compound (I) or a salt thereof and an amorphized polymer, or further an excipient, a binder, a disintegrant or other Add appropriate additives and mix evenly, then use appropriate methods such as extrusion granulation (granulation with an etustruder), extrusion granulation with heating, and stirring granulation (for example, mixing and stirring).
- Grain method High speed mixing and agitation granulation method, etc.
- fluidized bed granulation method rolling agitation fluidized bed granulation method
- rolling granulation method dry (compression) granulation method
- crushing granulation method spray drying granulation method
- the amorphous composition of the present invention may be further coated with a coating agent.
- the coating agent include ethyl acrylate 'methyl methacrylate copolymer dispersion, aminoalkyl methacrylate copolymers, ethyl cellulose, carboxymethyl ethyl cellulose, dry methacrylic acid copolymer LD, cellulose acetate phthalate, dimethylamino.
- Ethyl metatalylate 'methyl metatalylate copolymer stearic acid, hydroxypropyl methylcellulose phthalate, partially alpha starch, pullulan, polyoxyethylene (105) polyoxypropylene (5) glycol, polybutyl alcohol, methacrylic acid copolymers And magnesium aluminate metasilicate.
- the amorphous composition of the present invention preferably comprises a mixture of compound (I) or a salt thereof and HPMCAS in water and Z or an organic solvent (ethanol, acetone, isopropanol, etc., preferably ethanol and acetone). And the powdered amorphous composition can be granulated.
- the content of compound (I) is, for example, about 0.01 to about 60%, preferably about 3 to about 50% per formulation weight. It is preferable to do.
- amorphous composition of the present invention about 100 to about 350 parts by weight of HPMCAS is preferred with respect to 100 parts by weight of Compound (I), more preferably about 150 to about 300 parts by weight.
- the amorphous composition of the present invention can make the absorption pattern in the nasal cavity constant by appropriately adjusting the average particle diameter.
- the BA was high. Specifically, it is preferably about 50 to about 300 ⁇ m, more preferably about 50 to about 200 ⁇ m, even more preferably about 75 to about 180 ⁇ m, and particularly preferably about 100 to about 150 ⁇ m. If high BA is obtained by formulation, it is possible to reduce the dose of the drug and improve patient compliance.
- the average particle size refers to a particle size that represents a group of particles when the group of particles has a large number of non-uniform particle forces.
- the average particle diameter is the number average form, length average form, area average form, volume average diameter, etc. There is a diameter.
- the amorphous composition of the present invention includes those capable of ensuring the identity within the scope of the objects and effects of the present invention.
- the physical stability that is, the amorphous state
- the proportion of amorphous to the total composition is preferably about 30 to about 100%, more preferably about 50 to about 100%, and even more preferably about 70 to about 100%.
- the chemical stability of the compound (I) or a salt thereof is maintained over a long period of time.
- the compound (I) or The residual ratio of the salt is preferably about 90 to about 100%, more preferably about 95 to about 100%, and still more preferably about 97 to about 100%.
- the bioavailability (BA) of compound (I) or a salt thereof is preferably about 2 to about 60%. More preferably from about 5 to about 50%, even more preferably from about 7 to about 40%.
- Preferable administration methods are nasal administration and oral mucosal adhesion administration.
- the masking effect for eliminating the odor derived from the compound, or the odor that is stronger than the odor derived from the drug in order to enhance patient compliance is added a fragrance that has an aromatic effect to cover the odor!
- flavoring agents having a masking effect include trehalose, phosphoric acid, maltose, potassium dalconate, vanilla essential oil, vanilla essential oil, cardamom essential oil, and the like.
- a flavoring agent having a fragrance effect that is, a fragrance, herbal medicine ingredients (cinnamon powder, thin powder powder, Camphor powder, wikiweed powder, ginger powder, rosemary powder, perilla leaf powder, etc., natural aroma oil or extract (peppermint oil, spearmint oil, hearth oil, bergamot oil, tangierin oil, ylang ylang oil, rose oil, gelanum Oil, orange extract, turpentine oil, thiodi oil, lemon powder, vanilla essence, peppermint essence, eucalyptus oil, etc., various aromatic components (1-menthol, dl-menthol, camphor, vanillin, limonene, butanol, isobutyl alcohol, hexanol) , Hexanal, trans 2-hexenal, cinnamic alcohol, phenol propyl alcohol, cis-3-hexenol, ethyl butyrate, butyl acetate, butyl but
- the surface of the preparation can be treated with a masking agent (flavoring agent), or a powder or liquid extract having an aromatic effect before preparation is kneaded, It can be used as a preparation.
- a masking agent flavoring agent
- a powder or liquid extract having an aromatic effect before preparation is kneaded
- the compounding amount of compound (I) or a salt thereof in the amorphous composition of the present invention may be selected according to the amount necessary for activity and treatment, but in the unit dosage composition, However, it is preferable that the compound is formulated in consideration of the amount of the compound. In addition, for example, when the same container force is administered multiple times in various dosage forms, it is preferable that the dosage per dosage can be administered at a normal dosage or more.
- the amorphous composition of the present invention is administered nasally to mammals such as humans, it is widely used. It is possible to use a nasal powder sprayer such as a sanszer (Teijin), an insufflator (Phisons), a jet riser (Hitachi), and Bidose (Phifer).
- a nasal powder sprayer such as a marina, a slitol, a slitol, a slitota, or a jet riser (Hitachi), and Bidose (Phifer).
- the dose of compound (I) or a salt thereof contained in the composition to a human is about 5 to about 150 mgZ. More preferably, it is about 10 to about 90 mgZ, more preferably about 15 to about 50 mgZ.
- the amorphous composition of the present invention can be further tableted into a tablet to form an oral mucosa-adherent tablet.
- An oral mucosa-adherent tablet is a tablet that is intended for absorption from the oral mucosa and is affixed to the gingiva, heel, soft palate, etc. with the expectation of local or systemic effects.
- an amorphous composition that is a mixture of compound (I) or a salt thereof and HPMCAS is further added to excipients (latatose, mannitol, glucose, microcrystalline cellulose, starch, etc.). ), Binders (hydroxypropylcellulose, polyburpyoridone, magnesium aluminate metasilicate, etc.), disintegrants (calcium cellulose glycolate, etc.), lubricants (magnesium stearate, etc.), stabilizers, solubilizing agents ( It may be mixed with glutamic acid, aspartic acid, etc.) and used after tableting and formulation according to conventional methods. If necessary, it may be coated with a coating agent (sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.), or may be coated with two or more layers.
- excipients lacatatose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- Binders hydroxy
- the amorphous composition of the present invention can also be made into an oral mucosa-adhesive film formulation by being applied or embedded in a base.
- An oral mucosa-adhesive film preparation is a drug with active ingredients applied or embedded in the base, and is intended for absorption from the oral mucosa and is fixed to the gingiva, heel, soft palate, etc. with the expectation of local or systemic effects.
- a film agent is a drug with active ingredients applied or embedded in the base, and is intended for absorption from the oral mucosa and is fixed to the gingiva, heel, soft palate, etc. with the expectation of local or systemic effects.
- an amorphous composition that is a mixture of compound (I) or a salt thereof and HPMCAS can be applied or embedded in the base polymer.
- the base polymer is preferably, for example, carboxybule polymer, sodium carboxymethylcellulose, carrageenan, sodium alginate, propylene glycol alginate, xanthan gum, polyacrylic acid, sodium polyacrylate, tara gum, guagum, locust bean gum.
- Hydroxyethyl cellulose Hydroxyethyl cellulose, hydroxypropenoresenorelose, hydroxypropinolemethinoresenorelose, methinoresenorelose, dielan gum Gelatin, curdlan, gum arabic, agar, pectin, polyvinyl alcohol, pullulan and the like.
- the excipients lubricants, binders, disintegrants, thickeners, suspending agents, emulsifiers, isotonic agents, buffers, soothing agents, stabilizers, preservatives. (Preservatives), PH adjusters, refreshing agents, antioxidants, wetting agents, flavoring agents (masking agents) and other additives.
- the amorphous composition of the present invention is used as an oral mucosa-adhesive tablet or oral mucosa-adhesive film preparation for mammals such as humans, the compound (I) or a salt thereof contained in the entire composition is applied to humans.
- the dosage is about 1 to about 150 mgZ. More preferably, it is about 5 to about 90 mgZ, more preferably about 10 to about 50 mgZ. This preparation can be administered 5 times 1-5 times per day.
- the amorphous composition of the present invention has been found to exhibit a very high V BA and excellent physical properties.
- the amorphous composition of the present invention has very low toxicity and is sufficiently safe for use as a medicament.
- the amorphous composition of the present invention can reduce the dose by improving the BA of compound (I) or a salt thereof, and as a result, can be safely administered as a medicament.
- the compound (I) exhibits an excellent N-type calcium channel inhibitory action on mammals, particularly humans, and therefore has an N-type calcium channel-mediated disease such as pain (for example, neuropathic pain, cancer Pain, refractory pain, postoperative pain, acute pain, chronic pain, neuralgia, infectious pain, etc.), cerebral infarction, transient ischemic attack, cerebrospinal injury after cardiac surgery, spinal vascular disorder, stress Useful for prevention and Z or treatment of hypertension, neurosis, epilepsy, asthma, frequent urination, eye diseases (e.g. glaucoma, diabetic retinopathy, macular degeneration, retinal vascular occlusion, etc.)
- eye diseases e.g. glaucoma, diabetic retinopathy, macular degeneration, retinal vascular occlusion, etc
- neuropathic pain examples include postherpetic neuralgia (eg, postherpetic pain). Diabetic neuropathy, AIDS pain, trigeminal neuralgia, neuropathic back pain, etc. are particularly preferred.
- the amorphous composition of the present invention includes 1) prevention and Z or enhancement of Z or therapeutic effect of compound (I) or a salt thereof, and 2) kinetics of compound (I) or a salt thereof. It may be administered in combination with other drugs to improve absorption, reduce dosage, and reduce side effects of Z or 3) Compound (I) or its salts.
- the combination composition of the amorphous composition of the present invention and another drug may be administered in the form of a combination drug containing both components in one nasal preparation, or in a separate preparation. It may take the form of administration.
- simultaneous administration and administration by time difference are included.
- administration by time difference may be such that the preparation of the present invention is administered first and the other drug may be administered later, or the other preparation may be administered first and the preparation of the present invention may be administered later.
- Each method of administration may be the same or different.
- oral administration and parenteral administration for example, eye drops, inhalation, poultice, sticking, etc.
- the other drug may be a low molecular compound or a high molecular protein, polypeptide, polynucleotide (DNA, RNA, gene), antisense, decoy, antibody, or vaccine. Etc.
- the dosage of other drugs can be appropriately selected based on the clinically used dose.
- the compounding ratio of the compound of the present invention and other drugs can be appropriately selected depending on the age and weight of the administration subject, administration method, administration time, target disease, symptom, combination and the like. For example, 0.01 to 100 parts by weight of another drug may be used with respect to 1 part by weight of the compound of the present invention.
- the other drugs may be administered by combining one or two or more kinds arbitrarily selected from the following homogeneous groups and heterogeneous groups in an appropriate ratio.
- the disease that exerts the preventive and Z or therapeutic effect by the above concomitant agent is not particularly limited as long as it is a disease that complements and / or enhances the preventive and Z or therapeutic effect of the compound of the present invention.
- drugs for complementing and / or enhancing the effect of compound (I) or a salt thereof on pain include, for example, narcotic or non-narcotic analgesics, non-steroid anti-inflammatory drugs
- Antipyretic analgesic, antiepileptic, antiarrhythmic, antidepressant, anxiolytic, anti Examples include psychotic drugs, corticosteroids, antihistamines, local anesthetics, NMDA antagonists, unilateral pain treatments, painful diabetic neuropathy treatments, and calcium channel inhibitors.
- Narcotic or non-narcotic analgesics include, for example, opium, opium altoloids, opium alkaloids, opium alkaloids. Atoguchi pin, opium alkaloids 'scopolamine, morphine hydrochloride, morphine' Atoguchi Pin, ethyl morphine hydrochloride, compound oxycodone, compound oxycodone 'at mouth pin, codin phosphate, dihydrocodeine phosphate, oximetebanol, ***e hydrochloride, pethidine hydrochloride, fental citrate, pentazocine, pentazocine hydrochloride, tramadol hydrochloride , Butorphanol tartrate, buprenorphine hydrochloride, and eptazocine hydrobromide.
- Non-steroidal anti-inflammatory drugs include, for example, Sazapyrine, sodium salicylate, aspirin, aspirin 'dialuminate combination, diflu-sal, suprofen, ufenamate, dimethyl isopropylazulene, bufae exac, fuerbinac, tolmetin sodium, Talinolyl, napmetone, ibuprofen piconol, ketofenilbutazone, oxifenbutazone, napageln ointment, sulpyrine, migrenin, salidone, cedes G, amypiro-N, sorbone, pilin-type cold medicine, acetaminophen, phenacetin, methinoreic acid dimethothine Citride combination, non-pyrine cold remedy, salicylamide, flufenamic acid, flufenamic acid aluminum, mefenamic acid, mefenamic acid aluminum, fructaphenine, tolf
- antipyretic analgesics examples include sulpyrine, acetaminophen, dimethothiazine mesylate and the like.
- Antiepileptic drugs include, for example, qui-toin, ethotoin, phenobarbital, pheno Examples include sodium valpital, mehobarbital, metalbital, trimethadione, ethosuximide, acetylphenetride, primidone, sodium valproate, carbamazepine, zo-samide, acetazolamide, diazepam and the like.
- Antiarrhythmic drugs include, for example, apuridine hydrochloride, amiodarone hydrochloride, 1-isoprenalin, quinidine sulfate, dizoviramide, disoviramide phosphate, cibenzoline succinate, pyrmethanol hydrochloride, flecaide acetate, pillicide hydrochloride, Examples include hydrochloric acid pro-amide, propaphenone hydrochloride, mexiletine hydrochloride, lidocaine and the like.
- antidepressant examples include desipramine hydrochloride, nortriptyline hydrochloride, amoxapine, maprotiline hydrochloride, imibramine hydrochloride, amitriptyline hydrochloride, clomipramine hydrochloride, trimipramine maleate, oral fepramine hydrochloride, doslevine hydrochloride, trazodone hydrochloride, fluvoxamine maleate, Examples include paroxetine hydrochloride hydrate, milnacipran hydrochloride, and mianserin.
- Anti-anxiety drugs include, for example, alprazolam, etizolam, oxazolam, cloxazolam, clothiazebam, chlordiazepoxide, diazepam, fluzazepam, bromazepam, medazepam, ethylazepamate, lorazepam, hydroxyzine hydrochloride, vamoic acid Hydroxidine, flutazolam, tofuisobam and the like can be mentioned.
- Antipsychotics include, for example, chlorpromazine hydrochloride, thioridazine hydrochloride, probericazine, perphenazine, fluphenazine decanoate, levomepromazine maleate, spiperone, timiperone, neuroperidonore, decanoperole decanoate, bromperidole
- Examples include etatone, sulpiride, zotepine, pimozide, mosapramine hydrochloride, risperidone, perospyrone hydrochloride hydrate, taetiapine fumarate, and olanzapine.
- corticosteroids examples include dexamethasone, dexamethasone palmitate, triamcinolone acetonide, hydrocortisone, fludocortisone acetate, prednisolone betamethasone, methylprednisolone, and the like.
- Antihistamines include, for example, clemastine fumarate, d-chlorfelamine maleate, cyproheptadine hydrochloride, promethazine hydrochloride, homochlorcyclidine hydrochloride, mequitazine, diphenhydramine hydrochloride, ebastine, cetirizine hydrochloride, olopatadine hydrochloride, Examples include fluorinated sophenazine.
- Examples of the local anesthetic include ***e hydrochloride, bupiva hydrochloride inn, pro forcein hydrochloride, mepiba hydrochloride hydrochloride, dibu force in hydrochloride, tetracaine hydrochloride, lidocaine hydrochloride, sotalol hydrochloride and the like.
- Examples of the NMDA antagonist include ketamine, dextromedorphan, and the like.
- migraine treatment drugs include dihydroergotamine mesylate, lomerizine hydrochloride, sumatributane succinate, and the like.
- Examples of the therapeutic agent for painful diabetic neuropathy include mexiletine hydrochloride and the like.
- Examples of calcium channel inhibitors include gabapentin, technotide, tregilobaline, pregaparin and the like.
- the compound (I) or a salt thereof is preferably mixed with an amorphous polymer (for example, HPMCAS) so that the storage stability (physical and physical stability) is suitably improved.
- an amorphous polymer for example, HPMCAS
- HPMCAS amorphous polymer
- An excellent amorphous state can be provided.
- the plasma concentration transition between individuals as a preparation for nasal administration or an oral mucosa-absorbing preparation oral mucosa-adhering tablet or oral mucosa-adhering film preparation
- BA can be improved by reducing the difference and improving absorption in the body.
- the present invention provides a nasal preparation with improved compliance with reduced irritation in the nasal cavity by controlling the particle size of the composition. Furthermore, the present invention provides an oral mucosa-adhesive preparation that avoids irritation in the nasal cavity.
- FIG. 1 This shows the change in blood concentration over time when the preparations produced in Comparative Example 4 and Preparation Example 3 were administered nasally.
- the ⁇ mark is the formulation of Comparative Example 4 using HPMC
- the ⁇ mark is the formulation of Formulation Example 3 using HPMCAS.
- FIG. 2 shows the time course of blood concentration of Compound (I) according to each particle size distribution of the preparation.
- ⁇ mark is 10 6—150 / ⁇ ⁇ , 0 ⁇ ] [53-106 111, A 150-300 m particle size distribution.
- FIG. 3 Amorphous nasal preparation (0.03 mgZkg, 0.1 lmgZkg and 0.33 mgZkg) of HPMCAS and control preparation (HPMCAS) of compound (I) prepared in Formulation Example 5 for spinal nerve ligature monkeys ) Represents the change in the latency of pain response.
- HPMCAS trade name: AQOAT—LF (manufactured by Shin-Etsu Chemical Co., Ltd.)
- the solution obtained by adding 3 g) was spray-dried to obtain an amorphous powder.
- test example 1 Stability test test implementation method
- Amorphous powders from Formulation Examples 1 and 2 and Comparative Examples 1 to 3 produced in Formulation Example 1 were each sealed in silica gel with an aluminum pillow and sealed, and tested for stability under conditions after storage at 60 degrees Celsius for one month. Went. After completion of the test, chemical stability was evaluated (purity test), and physical stability was evaluated (X-ray diffraction analysis, differential scanning calorimetry (DSC)). The results of the chemical stability test are shown in Table 1 below, and the results of the physical stability test are shown in Table 2.
- “Amorphization (%)” in Table 2 is calculated by calculating the crystallization rate (%) of the endothermic peak force of the melting point obtained by DSC. (100—crystallization rate (%)) This is the value obtained in, and indicates the degree of amorphization. “Halo” represents an amorphous shape with no visible crystalline peak. In addition, as will be apparent to those skilled in the art, the ratio of amorphous ions can be calculated from the height of the crystalline peak in X-ray diffraction.
- HPMCAS or PVP are suitable for maintaining the point stability of physical stability.
- HPMCAS and HPC which are amorphized polymers, are suitable as the polymer that can ensure both chemical and physical stability, and HPMC AS is the most suitable.
- HPMCAS trade name: AQOAT—LF; 30 g
- HPMCAS trade name: AQOAT—LF; 30 g
- the mixture was sieved with a sieve having an opening of 300 m
- compound (I) (10 g) was dissolved in the sieved liquid to form a spray liquid, and spray-dried to obtain a powder.
- Magnesium stearate (80 mg) was added to the spray-dried powder (8 g), mixed with a mortar / pestle, and compressed with a roller compactor to obtain flakes. The flakes were crushed with a mortar 'pestle and sieved to obtain a fraction of 45 to 150 m to prepare a preparation.
- HPMCAS amorphous preparation (1. 406 g) produced in Formulation Example 3 and 75-106 ⁇ m fraction lactose for direct compression (8. 594 g) obtained by sieving Were mixed and filled into 2 capsules, one capsule per nose so that the dose of compound (I) was 0.4 mgZkg, and this was used as an HPMCAS-containing preparation.
- BA represents ((Nasal AUCZ Nasal Dose) Z (Intravenous AUCZ Intravenous Dose) X 100) (%), AUC is the blood concentration-time curve Represents the lower area (ng, hrZ mL).
- the results are shown in Figure 1.
- the BA values of the preparations of Comparative Example 4 and Preparation Example 3 are 1.8% and 10.1%, respectively.
- Comparative Example 4 and Preparation Example 3 were weighed into glass test tubes, respectively, capped, put in an aluminum pyrophore together with silica gel, and heat sealed. These were stored for 1 month in a thermostat (60 degrees Celsius) for stability testing. Thereafter, quantitative measurement, purity test, DSC and powder X-ray diffraction measurement were performed. Table 3 shows the results of physical stability and Table 4 shows the results of chemical stability.
- Absolute ethanol: Acetone 1: 1 (vZv) Dissolve HPMCAS (40g) in a mixed solution (lOOOmL) and then dissolve the compound (I) (20g). After spray-drying, the solution is 40 degrees Celsius overnight. Dry under reduced pressure.
- the resulting spray-dried powder (7.5 g) is mixed with Avicel PH101 (2.4 g) and magnesium stearate (lOOmg), mixed with a mortar and pestle, compressed into tablets and compressed into a molded product. Obtained.
- the molded body was crushed with a mortar and pestle, and fractions of 53 to 106, 106 to 150, 150 to 180 / ⁇ ⁇ were obtained by sieving. Each fractionated powder (lg) [magnesium stearate (10. lmg) was added to prepare a preparation.
- an amorphous composition having a particle size distribution of 106 to 150 ⁇ m has particularly excellent BA. From this, an amorphous composition having an average particle diameter in the range of about 100 to about 150 m, and an amorphous composition mainly containing these average particle diameters, that is, an average particle diameter of about 70 Amorphous compositions that are ⁇ 150 m are expected to have excellent BA values as well.
- Tablets were formed using the amorphous composition (spray-dried powder) produced in Formulation Example 4 to obtain tablets having the respective compositions shown in Table 7.
- the amorphous composition (spray-dried powder) produced in Formulation Example 4 and other components are uniformly dispersed in hexane so that the solid content is 10% by weight, and the dispersion is supported on a support ( PE film # 9720; made by 3M Healthcare Co., Ltd.) and spread with a baker applicator (made by Tester Sangyo Co., Ltd.) to a uniform thickness. This was dried under reduced pressure at room temperature for 18 hours, and the coated surface was covered with the inner surface of the liner (PET film “single-sided release # 1022; manufactured by 3M Healthcare Co., Ltd.”) to obtain a film preparation having the compositional power shown in Table 8.
- a physically and chemically stable amorphous composition can be obtained by granulating the compound (I) using a suitable amorphized polymer such as HPMCAS.
- a suitable amorphized polymer such as HPMCAS.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/722,008 US20080096924A1 (en) | 2004-12-17 | 2005-12-16 | Amorphous Composition |
JP2006548929A JPWO2006064906A1 (ja) | 2004-12-17 | 2005-12-16 | 非晶質性組成物 |
EP05816911A EP1829549A1 (en) | 2004-12-17 | 2005-12-16 | Amorphous composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004366081 | 2004-12-17 | ||
JP2004-366081 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006064906A1 true WO2006064906A1 (ja) | 2006-06-22 |
Family
ID=36587955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/023140 WO2006064906A1 (ja) | 2004-12-17 | 2005-12-16 | 非晶質性組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080096924A1 (ja) |
EP (1) | EP1829549A1 (ja) |
JP (1) | JPWO2006064906A1 (ja) |
WO (1) | WO2006064906A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009038112A1 (ja) * | 2007-09-21 | 2009-03-26 | Shionogi & Co., Ltd. | Npyy5受容体拮抗剤を含有する固形製剤 |
JP2010138124A (ja) * | 2008-12-12 | 2010-06-24 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜貼付製剤 |
JP2017048136A (ja) * | 2015-09-01 | 2017-03-09 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
KR20190038589A (ko) * | 2016-08-05 | 2019-04-08 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 비강내 제약 분말 조성물 |
EP3542862A1 (en) | 2018-03-22 | 2019-09-25 | Nitto Denko Corporation | Production method of pregabalin-containing composition and pregabalin-containing composition |
JP2022000430A (ja) * | 2012-11-14 | 2022-01-04 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012146A1 (en) * | 2007-07-02 | 2009-01-08 | Giridhar Reddy Buggana | Solubility-enhanced pharmaceutical compositions comprising zafirlukast |
US20110174228A1 (en) * | 2010-01-21 | 2011-07-21 | F&R Enterprises, Inc. | Hybrid animal litter composition |
KR102286952B1 (ko) * | 2013-12-31 | 2021-08-09 | 롯데정밀화학 주식회사 | 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0249728A (ja) * | 1988-05-30 | 1990-02-20 | Zeria Pharmaceut Co Ltd | ジヒドロピリジン化合物の製剤組成物 |
JPH09309834A (ja) * | 1996-03-18 | 1997-12-02 | Nissan Chem Ind Ltd | 塩酸エホニジピン製剤の製造法 |
JPH11116502A (ja) * | 1997-08-11 | 1999-04-27 | Pfizer Prod Inc | 噴霧乾燥固体分散系を含む組成物 |
WO2000000470A1 (fr) * | 1998-06-26 | 2000-01-06 | Ono Pharmaceutical Co., Ltd. | Derives d'acides amines et medicaments contenant lesdits derives en tant que principe actif |
JP2000229886A (ja) * | 1999-02-09 | 2000-08-22 | Pfizer Prod Inc | 優れた生物学的利用能を持つ塩基性薬剤組成物 |
WO2001037839A1 (fr) * | 1999-11-24 | 2001-05-31 | Taisho Pharmaceutical Co., Ltd. | Preparation s'administrant par voie nasale |
WO2003000294A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
JP2004534822A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 低溶解度および/または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物 |
WO2004113332A1 (ja) * | 2003-06-19 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 経鼻製剤 |
-
2005
- 2005-12-16 WO PCT/JP2005/023140 patent/WO2006064906A1/ja active Application Filing
- 2005-12-16 EP EP05816911A patent/EP1829549A1/en not_active Withdrawn
- 2005-12-16 JP JP2006548929A patent/JPWO2006064906A1/ja active Pending
- 2005-12-16 US US11/722,008 patent/US20080096924A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0249728A (ja) * | 1988-05-30 | 1990-02-20 | Zeria Pharmaceut Co Ltd | ジヒドロピリジン化合物の製剤組成物 |
JPH09309834A (ja) * | 1996-03-18 | 1997-12-02 | Nissan Chem Ind Ltd | 塩酸エホニジピン製剤の製造法 |
JPH11116502A (ja) * | 1997-08-11 | 1999-04-27 | Pfizer Prod Inc | 噴霧乾燥固体分散系を含む組成物 |
WO2000000470A1 (fr) * | 1998-06-26 | 2000-01-06 | Ono Pharmaceutical Co., Ltd. | Derives d'acides amines et medicaments contenant lesdits derives en tant que principe actif |
JP2000229886A (ja) * | 1999-02-09 | 2000-08-22 | Pfizer Prod Inc | 優れた生物学的利用能を持つ塩基性薬剤組成物 |
WO2001037839A1 (fr) * | 1999-11-24 | 2001-05-31 | Taisho Pharmaceutical Co., Ltd. | Preparation s'administrant par voie nasale |
WO2003000294A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
JP2004534822A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 低溶解度および/または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物 |
WO2004113332A1 (ja) * | 2003-06-19 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 経鼻製剤 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009038112A1 (ja) * | 2007-09-21 | 2011-01-06 | 塩野義製薬株式会社 | Npyy5受容体拮抗剤を含有する固形製剤 |
WO2009038112A1 (ja) * | 2007-09-21 | 2009-03-26 | Shionogi & Co., Ltd. | Npyy5受容体拮抗剤を含有する固形製剤 |
JP2010138124A (ja) * | 2008-12-12 | 2010-06-24 | Kyukyu Yakuhin Kogyo Kk | 口腔内粘膜貼付製剤 |
JP2022000430A (ja) * | 2012-11-14 | 2022-01-04 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
JP2017048136A (ja) * | 2015-09-01 | 2017-03-09 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
US10925861B2 (en) | 2015-09-01 | 2021-02-23 | Sawai Pharmaceutical Co., Ltd. | Mirabegron-containing tablet, method for producing mirabegron-containing pharmaceutical preparation, and method for producing mirabegron-containing granulated product |
WO2017038281A1 (ja) * | 2015-09-01 | 2017-03-09 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
KR20190038589A (ko) * | 2016-08-05 | 2019-04-08 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 비강내 제약 분말 조성물 |
JP2019527703A (ja) * | 2016-08-05 | 2019-10-03 | 株式会社新日本科学 | 鼻腔内薬学的粉末組成物 |
JP2022078268A (ja) * | 2016-08-05 | 2022-05-24 | 株式会社新日本科学 | 鼻腔内薬学的粉末組成物 |
KR102489453B1 (ko) * | 2016-08-05 | 2023-01-16 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 비강내 제약 분말 조성물 |
JP7366178B2 (ja) | 2016-08-05 | 2023-10-20 | 株式会社新日本科学 | 鼻腔内薬学的粉末組成物 |
US11872314B2 (en) | 2016-08-05 | 2024-01-16 | Shin Nippon Biomedical Laboratories, Ltd. | Pharmaceutical compositions |
EP3542862A1 (en) | 2018-03-22 | 2019-09-25 | Nitto Denko Corporation | Production method of pregabalin-containing composition and pregabalin-containing composition |
Also Published As
Publication number | Publication date |
---|---|
US20080096924A1 (en) | 2008-04-24 |
JPWO2006064906A1 (ja) | 2008-06-12 |
EP1829549A1 (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006064906A1 (ja) | 非晶質性組成物 | |
JP6173521B2 (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
EP3270696B1 (en) | Solid dispersions comprising ospemifene | |
JP7269227B2 (ja) | ニラパリブ処方物 | |
US20070071813A1 (en) | Novel dosage formulation | |
JP2005508865A (ja) | アポモルフィン、6aR−(−)−N−プロピル−ノルアポモルフィンおよびそれらの誘導体、並びにそれらのプロドラッグを効率的に投与するための薬学的処方剤 | |
JP2018035171A (ja) | 医薬製剤 | |
WO2008072534A1 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
TW200848056A (en) | Solid dispersion of a neurokinin antagonist | |
WO2007119792A1 (ja) | 乾式直打速崩壊性錠剤 | |
JP2008536922A (ja) | オランザピンの医薬用経口崩壊錠 | |
JP2023513444A (ja) | ダサチニブの非晶質固体分散体及びその使用 | |
ES2311230T3 (es) | Composicion farmaceutica que se desintegra oralmente que comprende risperidona. | |
IL293096A (en) | A pharmaceutical preparation for oral administration containing a carbamate compound and a method for its preparation | |
JP6680297B2 (ja) | 経口投与用医薬組成物 | |
JP2022514569A (ja) | 非晶質スパルセンタン組成物 | |
KR20150100734A (ko) | 유효 성분 조합물의 변형 방출을 위한 모놀리식 투여형 | |
ES2450944T3 (es) | Composición y comprimido que comprenden raltegravir | |
WO2009146608A1 (zh) | 含有咪唑5-羧酸类衍生物的药用组合物,其制备方法及用途 | |
US11285152B2 (en) | Stable oral pharmaceutical composition of imatinib | |
JP2006510665A (ja) | 新規な経口即時放出型投与剤形 | |
JP2018516942A (ja) | 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法 | |
EP2523657A1 (en) | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof | |
JP3934150B1 (ja) | 固形製剤および製剤組成物 | |
US20110038928A1 (en) | Orally disintegrating tablets of zolmitriptan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006548929 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005816911 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11722008 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005816911 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11722008 Country of ref document: US |